Literature DB >> 33738074

Novel Copper(II) Complex with a 4-Acylpyrazolone Derivative and Coligand Induce Apoptosis in Liver Cancer Cells.

Marhaba Nurmamat1, Haili Yan1, Ru Wang1, Huixin Zhao1, Yanhong Li1, Xiaojing Wang1, Kaidirye Nurmaimaiti1, Tamasha Kurmanjiang1, Difang Luo1, Jumagul Baodi1, Guancheng Xu2, Jinyu Li1.   

Abstract

A novel pyrazolone-based copper complex [CuL(phen)(CH3OH)][CuL(phen)]·CH3CH2OH·CH3OH (P-FAH-Cu-phen) was synthesized and characterized. The asymmetric structural unit of P-FAH-Cu-phen was composed of two independent complex units [CuL(phen)(CH3OH)] and [CuL(phen)]:Cu12+ center with six coordination mode and Cu22+ center with five coordination mode. The growth of BEL-7404 cells and H22 cells was significantly inhibited by P-FAH-Cu-phen with IC50 values of 1.175 μg/mL and 1.097 μg/mL, respectively, which were much lower than IC50 of cisplatin for BEL-7404 cells (23.32 μg/mL) and H22 cells (27.5 μg/mL). P-FAH-Cu-phen induced cell cycle arrest at G2/M and apoptosis in BEL-7404 cells through mitochondria- and endoplasmic reticulum stress-associated pathways. Moreover, P-FAH-Cu-phen significantly suppressed the migration of BEL-7404 cells and the tumor growth in H22 tumor mouse model without severe side effects and improved the survival of tumor mice. The results suggested that P-FAH-Cu-phen might be a potential drug candidate for the treatment of live cancer.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33738074      PMCID: PMC7957940          DOI: 10.1021/acsmedchemlett.0c00680

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

Review 1.  Control of mitochondrial permeability by Bcl-2 family members.

Authors:  Juanita C Sharpe; Damien Arnoult; Richard J Youle
Journal:  Biochim Biophys Acta       Date:  2004-03-01

2.  The status of platinum anticancer drugs in the clinic and in clinical trials.

Authors:  Nial J Wheate; Shonagh Walker; Gemma E Craig; Rabbab Oun
Journal:  Dalton Trans       Date:  2010-06-30       Impact factor: 4.390

Review 3.  Targeting copper in cancer therapy: 'Copper That Cancer'.

Authors:  Delphine Denoyer; Shashank Masaldan; Sharon La Fontaine; Michael A Cater
Journal:  Metallomics       Date:  2015-08-27       Impact factor: 4.526

4.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

Review 5.  Schiff bases in medicinal chemistry: a patent review (2010-2015).

Authors:  Abdul Hameed; Mariya Al-Rashida; Maliha Uroos; Syed Abid Ali; Khalid Mohammed Khan
Journal:  Expert Opin Ther Pat       Date:  2016-11-07       Impact factor: 6.674

Review 6.  Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives.

Authors:  Tatjana Lazarević; Ana Rilak; Živadin D Bugarčić
Journal:  Eur J Med Chem       Date:  2017-04-18       Impact factor: 6.514

Review 7.  Synthesis and Pharmacological Activities of Pyrazole Derivatives: A Review.

Authors:  Khalid Karrouchi; Smaail Radi; Youssef Ramli; Jamal Taoufik; Yahia N Mabkhot; Faiz A Al-Aizari; M'hammed Ansar
Journal:  Molecules       Date:  2018-01-12       Impact factor: 4.411

Review 8.  Non platinum metal complexes as anti-cancer drugs.

Authors:  Ingo Ott; Ronald Gust
Journal:  Arch Pharm (Weinheim)       Date:  2007-03       Impact factor: 3.751

9.  Cold-inducible protein RBM3 mediates hypothermic neuroprotection against neurotoxin rotenone via inhibition on MAPK signalling.

Authors:  Hai-Jie Yang; Rui-Juan Zhuang; Yuan-Bo Li; Tian Li; Xin Yuan; Bing-Bing Lei; Yun-Fei Xie; Mian Wang
Journal:  J Cell Mol Med       Date:  2019-08-22       Impact factor: 5.310

10.  Metal Complexes of New Bioactive Pyrazolone Phenylhydrazones; Crystal Structure of 4-Acetyl-3-methyl-1-phenyl-2-pyrazoline-5-one phenylhydrazone Ampp-Ph.

Authors:  Omoruyi G Idemudia; Alexander P Sadimenko; Eric C Hosten
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.